Sab bio to participate in upcoming investor conferences

Miami, jan. 31, 2025 (globe newswire) -- sab bio (nasdaq: sabs), (“sab bio” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing sab-142, a human anti-thymocyte immunoglobulin (higg) that potentially delays the onset or progression of type 1 diabetes (t1d), today announced that members of its management team will participate in the following investor conferences:
SABS Ratings Summary
SABS Quant Ranking